Grifols (NASDAQ:GRFS) Downgraded to Buy Rating by Wall Street Zen

Wall Street Zen cut shares of Grifols (NASDAQ:GRFS) from a strong-buy rating to a buy rating in a research note issued to investors on Saturday.

GRFS has been the subject of several other research reports. JPMorgan Chase & Co. dropped their price target on shares of Grifols from $10.30 to $10.00 and set a “neutral” rating for the company in a research note on Monday, December 8th. Weiss Ratings reiterated a “hold (c)” rating on shares of Grifols in a research report on Thursday, January 22nd. Finally, Zacks Research raised Grifols from a “strong sell” rating to a “hold” rating in a research note on Friday, February 6th. Four equities research analysts have rated the stock with a Hold rating, Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $10.00.

Grifols Trading Up 1.6%

NASDAQ GRFS opened at $9.10 on Friday. The business’s fifty day simple moving average is $9.22 and its 200-day simple moving average is $9.35. The company has a current ratio of 2.48, a quick ratio of 0.93 and a debt-to-equity ratio of 1.20. Grifols has a 52 week low of $6.19 and a 52 week high of $11.14.

Institutional Investors Weigh In On Grifols

A number of institutional investors have recently modified their holdings of the company. Bank of Montreal Can lifted its stake in Grifols by 3,205.1% during the 3rd quarter. Bank of Montreal Can now owns 3,013,723 shares of the biotechnology company’s stock worth $30,017,000 after acquiring an additional 2,922,540 shares in the last quarter. Brandes Investment Partners LP lifted its position in shares of Grifols by 8.9% during the second quarter. Brandes Investment Partners LP now owns 28,035,461 shares of the biotechnology company’s stock worth $253,441,000 after purchasing an additional 2,294,113 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its position in shares of Grifols by 383.7% during the third quarter. Arrowstreet Capital Limited Partnership now owns 2,800,645 shares of the biotechnology company’s stock worth $27,894,000 after purchasing an additional 2,221,633 shares in the last quarter. Norges Bank acquired a new stake in Grifols during the 2nd quarter worth approximately $17,538,000. Finally, Barclays PLC boosted its position in Grifols by 132.6% in the 4th quarter. Barclays PLC now owns 2,434,636 shares of the biotechnology company’s stock valued at $22,764,000 after buying an additional 1,387,783 shares during the period.

Grifols Company Profile

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.